The company is currently seeking interest from companies who have the skill and means to rapidly advance BOLD-100 for the treatment of COVID-19.

The partnership will focus on the development of up to five novel protein replacement and mRNA therapies.

S is now permitted to import human blood/blood products, other bodily fluids, and tissues that may contain novel coronavirus into its Newark, DE, facility.

The measurement device comes with an infrared semiconductor to examine the molecular structure of materials in a wavelength range up to 2,5 µm for factory and lab applications.

The system, which works to miniaturize, integrate, and automate bioanalytical processes, will give JIB students enrolled in the school’s specialist graduate, PhD, and industry training programs the ability to enhance their industry skills via access to Gyrolab systems and ready-to-use kits.

The Lanexo Lab Inventory, Safety, and Compliance Management System is a digital laboratory informatics solution formulated to reduce time in labs and improve data quality and traceability.

Pre-clinical immunization studies of iBio’s SARS-CoV-2 VLP candidates are being performed by Texas A&M.

The bill includes multiple less-noticed provisions to bolster healthcare programs and to advance the development of new treatments and preventives to combat the virus.

Johnson & Johnson announces clinical trial plans for COVID-19 vaccine candidate, as well as plans to produce 1 billion vaccine doses.

AzarGen’s biosimilar, made in iBio’s plant-based system, will be compared to the original molecule in pre-clinical studies.

ProBioGen will facilitate the development of Immunogenesis’ monoclonal antibody candidate and will be responsible for manufacturing the drug at its new facility in Berlin, Germany.

The companies will use CytomX’s Probody therapeutic technology platform and its proprietary bispecific formats and CD3 modules.

The company is developing the first humanized antibody that can control the inflammatory response and prevent uncontrolled inflammation connected to the virus.

Data and analytics company GlobalData announced that there is a strain on the global biopharma industry’s supply chain due to the ongoing outbreak of COVID-19.

Prior to the global market downturn, data from the United Kingdom BioIndustry Association (BIA) and Informa Pharma Intelligence have revealed that biotech companies in the UK had raised £309 million (US$379 million).

AstraZeneca has announced that it has achieved approval in Japan for Lokelma (sodium zirconium cyclosilicate) for the treatment of patients with hyperkalemia (elevated blood potassium levels).

Mylan and Pfizer announced a postponement of the transaction that would see Mylan and Upjohn Combined until the second half of the year as a result of the current COVID-19 pandemic.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the latest statement by the members of the European Council on efforts to tackle COVID-19.

AstraZeneca has revealed that it will collaborate with Silence Therapeutics on the discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases.

Grifols has entered into a formal collaboration with US Federal public health agencies, including the Biomedical Advanced Research Development Authority (BARDA) and the Food and Drug Administration (FDA), to produce a treatment that specifically targets COVID-19.

The strategic alliance provides an integrated product offering around drug discovery and development.

The company has developed mathematical algorithms that generate simple cell-count data from a few days of culture.

The new NAB Nanosep device provides increased binding capacity.

The company has launched new high volume eight- and 12-channel pipettes, offering a capacity of 1250 µL per channel.

The transgenic mouse R&D platform will support the discovery of fully-human monoclonal antibodies.

Noting traditional clinical trials for COVID-19 convalescent plasma will take time, FDA is allowing physicians to submit requests for single-patient emergency INDs.

Bayer, Novartis, Mylan, Teva, report that they are working on supply.

In light of the current COVID-19 pandemic, the agencies co-chaired the first global regulators meeting to facilitate development of vaccines against SARS-CoV-2, which causes COVID-19.